⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7774252 | 0.97 | — | — | |
| SCHEMBL10490994 | 0.80 | — | — | |
| SCHEMBL6557505 | 0.78 | APP (0.43) | — | |
| SCHEMBL6831858 | 0.78 | — | — | |
| SCHEMBL1931721 | 0.76 | APLNR (0.35) | — | |
| SCHEMBL6557464 | 0.76 | DNM1 (0.44) | — | |
| SCHEMBL6557470 | 0.76 | DNM1 (0.44) | — | |
| SCHEMBL6357573 | 0.72 | — | — | |
| SCHEMBL2021636 | 0.71 | — | — | |
| Taurine SCHEMBL15531654 | 0.71 | LMNA (0.82) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| CN-110128367-A | A kind of indoles amine -2,3- dioxygenase inhibitor and its preparation method and application | 成都海创药业有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10173991-B2 | Sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| CN-101180296-B | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors | SANOFI AVENTIS | 2011-10-19 | — | — | CN | disclosed |
| WO-2010147836-A9 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010132839-A9 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7858820-B2 | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and the alkanoyl L-carnitines with taurine chloride and glycine chloride | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-28 | — | — | US | disclosed |
| WO-2010132768-A1 | ANTIBACTERIAL DERIVATIVES OF SISOMICIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7053076-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060030551-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2006-02-09 | — | — | US | disclosed |
| EP-1330428-B1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE | SIGMA TAU IND FARMACEUTI (IT) | 2005-12-14 | — | — | EP | disclosed |
| CN-1219748-C | Solid compositions suitable for oral administration containing non-hydroscopic salts of L-carnitine and alkanoyl L-carnitines with taurine chloride and glycine chloride | SIGMA TAU IND FARMACEUTI (IT) | 2005-09-21 | — | — | CN | disclosed |
| US-20040024061-A1 | Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride | ALFASIGMA S.P.A. (IT) | 2004-02-05 | — | — | US | disclosed |
| CN-1473144-A | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and alkanoyl L-carnitines with taurine chloride and glycine chloride | ϣ��������ҩ��ҵ��˾ | 2004-02-04 | — | — | CN | disclosed |
| EP-1330428-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE AND GLYCINE CHLORIDE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2003-07-30 | — | — | EP | disclosed |
| US-20030130246-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003020214-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002036543-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE AND GLYCINE CHLORIDE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-10 | — | — | WO | disclosed |